Positive News SentimentPositive NewsNASDAQ:QNRX Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis $6.00 -0.37 (-5.82%) As of 12:11 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Quoin Pharmaceuticals Stock (NASDAQ:QNRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quoin Pharmaceuticals alerts:Sign Up Key Stats Today's Range$5.93▼$6.4050-Day Range$5.45▼$9.2752-Week Range$5.20▼$41.80Volume17,799 shsAverage Volume78,443 shsMarket Capitalization$10.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Read More Quoin Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreQNRX MarketRank™: Quoin Pharmaceuticals scored higher than 22% of companies evaluated by MarketBeat, and ranked 810th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingQuoin Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageQuoin Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Quoin Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Quoin Pharmaceuticals is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quoin Pharmaceuticals is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuoin Pharmaceuticals has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.16% of the float of Quoin Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverQuoin Pharmaceuticals has a short interest ratio ("days to cover") of 2.26, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quoin Pharmaceuticals has recently decreased by 14.76%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuoin Pharmaceuticals does not currently pay a dividend.Dividend GrowthQuoin Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.1 / 5News Sentiment1.50 News SentimentQuoin Pharmaceuticals has a news sentiment score of 1.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Quoin Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest1 people have searched for QNRX on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Quoin Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Quoin Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders13.46% of the stock of Quoin Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions8.63% of the stock of Quoin Pharmaceuticals is held by institutions.Read more about Quoin Pharmaceuticals' insider trading history. Receive QNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quoin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QNRX Stock News HeadlinesQuoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 7 at 8:30 AM | globenewswire.comQuoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026April 30, 2026 | globenewswire.comSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses an emerging potential $10 trillion technology backed by Elon Musk and Sam Altman. This breakthrough could completely replace our need for foreign oil - and send one small group of stocks soaring in the process.May 8 at 1:00 AM | Altimetry (Ad)CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development ProgramsApril 28, 2026 | globenewswire.comQuoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development ProgramsApril 28, 2026 | globenewswire.comQNRX: Preparing to Commercialize Lead Asset Through Global Sales InfrastructureApril 15, 2026 | msn.comMaxim Group Sticks to Its Buy Rating for Quoin Pharmaceuticals (QNRX)April 11, 2026 | theglobeandmail.comQuoin Pharmaceuticals - Depositary Receipt (QNRX) price target increased by 12.66% to 30.26April 10, 2026 | msn.comSee More Headlines QNRX Stock Analysis - Frequently Asked Questions How have QNRX shares performed this year? Quoin Pharmaceuticals' stock was trading at $14.43 on January 1st, 2026. Since then, QNRX stock has decreased by 58.2% and is now trading at $6.0320. How were Quoin Pharmaceuticals' earnings last quarter? Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($1.77) EPS for the quarter, beating the consensus estimate of ($2.17) by $0.40. When did Quoin Pharmaceuticals' stock split? Quoin Pharmaceuticals's stock reverse split on the morning of Monday, July 17th 2023.The 1-12 reverse split was announced on Monday, July 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Quoin Pharmaceuticals IPO? Quoin Pharmaceuticals (QNRX) raised $0 in an initial public offering (IPO) on Friday, July 29th 2016. The company issued 1,292,308 shares at $0.00 per share. How do I buy shares of Quoin Pharmaceuticals? Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quoin Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quoin Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Zomedica (ZOM) and Abbott Laboratories (ABT). Company Calendar Last Earnings5/07/2026Today5/08/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 11 days, QNRX's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryMedical Equipment Current SymbolNASDAQ:QNRX CIK1671502 Webquoinpharma.com Phone(703) 980-4182Fax972-9767-8750Employees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)($34.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.81 million Net MarginsN/A Pretax MarginN/A Return on Equity-535.00% Return on Assets-223.99% Debt Debt-to-Equity RatioN/A Current Ratio3.61 Quick Ratio3.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$15.64 per share Price / Book0.39Miscellaneous Outstanding Shares1,800,000Free Float1,561,000Market Cap$10.86 million OptionableNot Optionable Beta1.61 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:QNRX) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | Sponsored‘Please’: OpenAI CEO Sam Altman Begs Small Company for HelpSpaceX 'Dark Energy' Replaces Foreign Oil For years, we've been told SpaceX is a rocket company. But accord...Altimetry | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quoin Pharmaceuticals, Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Quoin Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
